RCUSArcus Biosciences, Inc.
$18.53+12% 1Y
$18.53
$16.4752 weeks$31.57
Is the price fair?
What RCUS's price assumes
Arcus Biosciences, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 20.2× revenue.
20.2
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 5.09
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 15.0
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 5.09
- EV / EBIToperating margin −415%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 15.0
- Market capitalisation127.3 million shares, counted Jul 30, 2026
- $2.36B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks